Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AFMD Affimed	$0.18 -34.9%	$0.25	$0.07 ▼ $5.48	$2.92M	2.07	4.87 million shs	22.99 million shs
BCDA BioCardia	$1.96 +1.0%	$2.08	$1.63 ▼ $4.66	$11.25M	0.81	650,734 shs	23,061 shs
ERNA Ernexa Therapeutics	$1.38 -0.7%	$1.81	$1.37 ▼ $28.65	$10.66M	5.42	39,165 shs	60,189 shs
PCSA Heatwurx	$0.21 -0.6%	$0.22	$0.15 ▼ $1.50	$10.72M	1.32	5.32 million shs	1.02 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AFMD Affimed	0.00%	0.00%	0.00%	0.00%	-95.68%
BCDA BioCardia	-1.02%	+6.01%	-15.28%	-10.19%	-21.14%
ERNA Ernexa Therapeutics	-6.71%	-10.32%	-27.23%	-59.53%	-94.83%
PCSA Heatwurx	-4.79%	+2.85%	-8.03%	-29.78%	-85.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AFMD Affimed	1.7904 of 5 stars	3.0	0.0	4.3	0.0	0.0	1.3
BCDA BioCardia	3.8658 of 5 stars	3.8	5.0	0.0	3.6	2.5	0.6
ERNA Ernexa Therapeutics	0.7747 of 5 stars	0.0	3.0	0.0	3.3	1.7	0.0
PCSA Heatwurx	3.1603 of 5 stars	3.3	4.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AFMD Affimed	2.00	Hold	$3.62	1,895.87% Upside
BCDA BioCardia	3.50	Strong Buy	$25.00	1,178.77% Upside
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
PCSA Heatwurx	2.50	Moderate Buy	$2.00	847.87% Upside

Current Analyst Ratings Breakdown

Latest AFMD, ERNA, BCDA, and PCSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/26/2025	PCSA Heatwurx	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AFMD Affimed	$877K	3.33	N/A	N/A	$4.19 per share	0.04
BCDA BioCardia	$60K	188.98	N/A	N/A	($0.33) per share	-5.92
ERNA Ernexa Therapeutics	$580K	18.50	N/A	N/A	$0.58 per share	2.41
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AFMD Affimed	-$114.66M	N/A	0.00	N/A	N/A	-7,836.26%	-193.84%	-107.24%	9/1/2025 (Estimated)
BCDA BioCardia	-$7.95M	-$1.85	N/A	N/A	N/A	N/A	-19,117.42%	-246.92%	11/11/2025 (Estimated)
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-682.08%	11/10/2025 (Estimated)
PCSA Heatwurx	-$11.85M	-$2.32	N/A	N/A	N/A	N/A	-342.36%	-243.48%	10/29/2025 (Estimated)

Latest AFMD, ERNA, BCDA, and PCSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ERNA Ernexa Therapeutics	N/A	-$0.61	N/A	-$0.61	N/A	N/A
8/11/2025	Q2 2025	BCDA BioCardia	-$0.50	-$0.40	+$0.10	-$0.40	N/A	N/A
8/7/2025	Q2 2025	PCSA Heatwurx	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AFMD Affimed	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AFMD Affimed	0.13	1.93	1.93
BCDA BioCardia	N/A	0.33	0.33
ERNA Ernexa Therapeutics	N/A	1.81	1.81
PCSA Heatwurx	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AFMD Affimed	30.82%
BCDA BioCardia	20.57%
ERNA Ernexa Therapeutics	70.55%
PCSA Heatwurx	91.93%

Insider Ownership

Company	Insider Ownership
AFMD Affimed	3.80%
BCDA BioCardia	20.00%
ERNA Ernexa Therapeutics	1.50%
PCSA Heatwurx	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AFMD Affimed	200	16.10 million	15.49 million	Optionable
BCDA BioCardia	40	5.80 million	4.64 million	Optionable
ERNA Ernexa Therapeutics	10	7.67 million	7.56 million	No Data
PCSA Heatwurx	20	50.35 million	49.14 million	Not Optionable

AFMD, ERNA, BCDA, and PCSA Headlines

Recent News About These Companies

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

August 7, 2025 | globenewswire.com

Processa Pharmaceuticals Provides Portfolio and Business Update

July 1, 2025 | globenewswire.com

Processa Pares Gains on Equity Offer News

June 17, 2025 | marketwatch.com

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

June 17, 2025 | globenewswire.com

Processa Pharmaceuticals Enters Exclusive Licensing Agreement with Intact Therapeutics for PCS12852, Potential Treatment for Gastroparesis

June 17, 2025 | quiverquant.comQ

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

June 17, 2025 | globenewswire.com

Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention

June 15, 2025 | nasdaq.com

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

June 13, 2025 | globenewswire.com

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025 | globenewswire.com

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

April 15, 2025 | markets.businessinsider.com

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

April 15, 2025 | globenewswire.com

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

March 18, 2025 | globenewswire.com

Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently

February 21, 2025 | insidermonkey.com

Processa Pharmaceuticals faces Nasdaq delisting risk over share price

February 10, 2025 | msn.com

Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock

February 7, 2025 | finance.yahoo.com

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

February 7, 2025 | globenewswire.com

Processa Pharmaceuticals Closes $5 Million Public Offering with CEO and Institutional Investor Participation

January 30, 2025 | quiverquant.comQ

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

January 30, 2025 | globenewswire.com

Processa Pharmaceuticals director David Young buys $99,288 in stock

January 30, 2025 | msn.com

Processa Pharmaceuticals' chief business officer buys $34,691 in stock

January 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AFMD, ERNA, BCDA, and PCSA Company Descriptions

Affimed NASDAQ:AFMD

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

BioCardia NASDAQ:BCDA

$1.96 +0.02 (+1.03%)

Closing price 03:59 PM Eastern

Extended Trading

$1.96 +0.00 (+0.20%)

As of 05:52 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Ernexa Therapeutics NASDAQ:ERNA

$1.38 -0.01 (-0.72%)

Closing price 03:59 PM Eastern

Extended Trading

$1.48 +0.11 (+7.61%)

As of 06:56 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Heatwurx NASDAQ:PCSA

$0.21 0.00 (-0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$0.20 -0.01 (-3.59%)

As of 07:58 PM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time